Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLMN2F)

Drug Name

CM-AT Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[1]
Autism spectrum disorder	6A02	Phase 3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Chymotrypsin (CTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pancrecarb	DMOML9Q	Pancreatic malfunction	DC30-DC3Z	NDA filed	[3]
Liprotamase	DMNF4UH	Cystic fibrosis	CA25	Phase 3	[4]
POP-1	DMVTKCX	Solid tumour/cancer	2A00-2F9Z	Investigative	[3]
JBP-1	DM0KMPN	Solid tumour/cancer	2A00-2F9Z	Investigative	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT00881452) A Trial of CM-AT in Children With Autism. U.S. National Institutes of Health.
2	Drugmakers dance with autism. Nat Biotechnol. 2010 Aug;28(8):772-4.
3	US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
4	Clinical pipeline report, company report or official report of Anthera Pharmaceuticals.